Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salim Mujais

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
The Journal of Urology|May 6, 2024
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE TrialDavid Staskin, Janet Owens-Grillo, Elizabeth Thomas, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|January 8, 2008
Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell studyWei Fang, Robert Mullan, Hemal Shah, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 18, 2008
Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trialRamon Paniagua, Dante Amato, Salim Mujais, et al.
Journal of the American Society of Nephrology : JASN|April 19, 2002
Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trialRamón Paniagua, Dante Amato, Edward Vonesh, et al.
Urology|September 3, 2025
Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE TrialKenneth M Peters, Janet Owens-Grillo, Elizabeth Thomas, et al.
Clinical Drug Investigation|May 15, 2015
Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjectsHiroyuki Oshima, Takao Yamazaki, Lauren Benner, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|April 28, 2010
Glucoregulatory hormones and choice of osmotic agent in peritoneal dialysisSalim Mujais, Shruti N Tapiawala, Paul Yip, et al.
European Journal of Clinical Pharmacology|March 9, 2017
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokineticsRobert W Townsend, Shahzad Akhtar, Harry Alcorn, et al.
The Journal of Urology|December 18, 2024
Gene Therapy With URO-902 (pVAX/<i>hSlo</i>) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a TrialEkene A Enemchukwu, Susan Kalota, Kaiser Robertson, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 7, 2008
Health-related quality of life and hemoglobin levels in chronic kidney disease patientsFredric O Finkelstein, Kenneth Story, Catherine Firanek, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
The Journal of Urology|May 6, 2024
Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE TrialDavid Staskin, Janet Owens-Grillo, Elizabeth Thomas, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|January 8, 2008
Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell studyWei Fang, Robert Mullan, Hemal Shah, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 18, 2008
Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trialRamon Paniagua, Dante Amato, Salim Mujais, et al.
Journal of the American Society of Nephrology : JASN|April 19, 2002
Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trialRamón Paniagua, Dante Amato, Edward Vonesh, et al.
Urology|September 3, 2025
Clinically Meaningful Improvements With Vibegron in Men With Overactive Bladder and Benign Prostatic Hyperplasia: A Responder Analysis of the Phase 3 COURAGE TrialKenneth M Peters, Janet Owens-Grillo, Elizabeth Thomas, et al.
Clinical Drug Investigation|May 15, 2015
Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjectsHiroyuki Oshima, Takao Yamazaki, Lauren Benner, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|April 28, 2010
Glucoregulatory hormones and choice of osmotic agent in peritoneal dialysisSalim Mujais, Shruti N Tapiawala, Paul Yip, et al.
European Journal of Clinical Pharmacology|March 9, 2017
Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokineticsRobert W Townsend, Shahzad Akhtar, Harry Alcorn, et al.
The Journal of Urology|December 18, 2024
Gene Therapy With URO-902 (pVAX/<i>hSlo</i>) for the Treatment of Female Patients With Overactive Bladder and Urge Urinary Incontinence: Safety and Efficacy From a Randomized Phase 2a TrialEkene A Enemchukwu, Susan Kalota, Kaiser Robertson, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 7, 2008
Health-related quality of life and hemoglobin levels in chronic kidney disease patientsFredric O Finkelstein, Kenneth Story, Catherine Firanek, et al.
Pageof 4